ImmunoGen Inks Pact With Takeda To Develop ELAHERE Ovarian Cancer Drug In Japan
Portfolio Pulse from Nabaparna Bhattacharya
ImmunoGen (NASDAQ:IMGN) has signed an agreement with Takeda Pharmaceutical (NYSE:TAK) to develop and commercialize the ovarian cancer drug ELAHERE in Japan. ImmunoGen will receive $34 million in upfront and near-term milestone payments and is also eligible for potential regulatory and commercial milestone payments. ImmunoGen retains exclusive production rights and will supply the product for development and commercial use in Japan, while Takeda will receive an exclusive license to develop and commercialize ELAHERE in Japan.
August 28, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ImmunoGen's partnership with Takeda for the development and commercialization of ELAHERE in Japan could potentially increase its revenues.
The partnership with Takeda will provide ImmunoGen with upfront and milestone payments, as well as potential regulatory and commercial milestone payments. This could significantly increase ImmunoGen's revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Takeda's exclusive license to develop and commercialize ELAHERE in Japan could potentially increase its product portfolio and revenues.
The exclusive license to develop and commercialize ELAHERE in Japan will allow Takeda to expand its product portfolio and potentially increase its revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100